Unaudited financial results for the quarter and nine months ended December 31, 2025

Net loss reportedRevenue growth above 20%Exceptional itemResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.0%Reaction day

₹40.00

prior close

₹40.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.5%-3.5% vs market

Pharmaceuticals peers, median of 156sector-0.9%-4.1% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 4.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.0-1.5-3.5-0.9-4.1

Next day

-3.9-2.2-1.7-1.4-2.5

-11.0-1.2-9.8-0.9-10.1

-13.7-0.9-12.8-0.5-13.3

-12.5-2.3-10.2-2.0-10.5

-10.0-2.5-7.5-2.2-7.8

-15.3-3.6-11.7-2.8-12.5

15d

-15.0-10.4-4.6-6.9-8.1

-15.7-11.3-4.4-8.6-7.1

-23.0-3.6-19.4-3.4-19.6

-27.8+3.9-31.6+0.9-28.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Pharmaids Pharmaceuticals reported weak standalone Q3 FY26 results with revenue from operations of just Rs. 83.28 lakhs, sharply down from Rs. 596.55 lakhs in the previous quarter, though on a year-on-year basis the 9-month standalone revenue jumped to Rs. 791.36 lakhs from Rs. 220.84 lakhs. On a consolidated basis, 9-month revenue grew 41% YoY to Rs. 2,069.85 lakhs (from Rs. 1,467.93 lakhs). Losses, however, continued to widen: standalone loss for 9M FY26 stood at Rs. (912.51) lakhs versus Rs. (422.28) lakhs a year ago, while consolidated loss rose to Rs. (1,048.70) lakhs from Rs. (870.21) lakhs. Exceptional items of Rs. 313.08 lakhs (standalone) and Rs. 255.40 lakhs (consolidated) were recorded. The company also disclosed discontinuation of its lease with Koye Lifesciences Private Limited effective December 1, 2025. The auditor (PPKG & Co) issued an unqualified limited review report. Other equity at Rs. 2,852.10 lakhs (standalone) is now well below the Rs. 3,526.78 lakhs paid-up capital, indicating heavily eroded net worth.

Likely market impact

The deepening losses and eroded equity base are serious red flags for shareholders despite revenue growth on a consolidated basis. The stock is likely to remain under pressure until the company demonstrates a credible path to profitability.